Albumin peptide composition for improving hypoproteinemia as well as preparation method and application thereof

Abstract

The invention provides an albumin peptide composition for improving hypoproteinemia as well as a preparation method and application of the albumin peptide composition. The albumin peptide composition for improving the hypoproteinemia is prepared from the following raw materials in parts by mass: 12 to 20 parts of albumin peptide, 1 to 3 parts of oligomeric albumin peptide concentrated solution, 4 to 9 parts of rice protein peptide, 1 to 4 parts of liver protein hydrolysate, 0.05 to 0.1 part of vitamin C, 1 to 3 parts of xylitol, 1 to 3 parts of fructo-oligosaccharide, 0.5 to 2 parts of stachyose, 0.05 to 0.2 part of yeast glucan, 0.008 to 0.04 part of taurine and 0.0001 to 0.0002 part of sucralose. , 2-10 parts of apple juice, and 2-10 parts of blueberry juice. The albumin peptide composition for improving the hypoproteinemia has the beneficial effects that the albumin peptide composition for improving the hypoproteinemia can effectively provide high-quality nutrition for an organism, is beneficial to postoperative rehabilitation, contributes to protein supplement of a patient with the hypoproteinemia, and contributes to albumin synthesis of the organism.

Description

Technical Field

[0001] The present application belongs to the field of food, and specifically relates to an albumin peptide composition for improving hypoproteinemia, and a preparation method and application thereof. Background Art

[0002] Cancer patients are a high-risk group for malnutrition. Patients with digestive tract tumors are affected by the disease, and their digestive tract function is weakened, which affects the body's normal digestion and absorption of food. Compared with other cancer patients, they are more prone to malnutrition. Reasonable nutritional therapy is not only beneficial to improving the quality of life of cancer patients and reducing complications, but also can reduce treatment costs and improve prognosis. The tissue protein of various organs in a healthy body mainly comes from a normal diet, while the body's digestion and absorption, protein synthesis disorders and consumption, as well as high-intensity exercise and labor loss in a diseased state will lead to insufficient albumin levels in the body, resulting in hypoproteinemia, which is mainly manifested as malnutrition. Hypoproteinemia, also known as malnutrition edema, is a nutritional deficiency characterized by a decrease in plasma protein and a decrease in colloid osmotic pressure due to a long-term negative nitrogen balance in the body, which is very likely to cause systemic edema.

[0003] Hypoproteinemia is one of the common complications of most tumor surgery or radiotherapy and chemotherapy, and is a risk factor for poor prognosis. Studies have shown that plasma albumin content is negatively correlated with the risk of death. The incidence of complications in critically ill patients with albumin below 25 g / L is increased by 4 times, and the mortality rate is increased by 6 times. Hill et al. showed that the incidence of hypoproteinemia after major abdominal surgery can reach 70%-80%. Many studies have reported that early postoperative hypoproteinemia is closely related to poor clinical prognosis, and can be directly or indirectly used as an effective predictor of early complications, overall survival, and progression-free survival. Therefore, for patients with hypoproteinemia, effective supplementation of sufficient protein for precise nutritional intervention is crucial to correct negative nitrogen balance, promote wound healing, maintain the body's immunity, and improve the nutritional status of patients. The treatment strategy for hypoproteinemia is important to treat the primary disease and appropriate nutritional therapy. Scientific and reasonable precise nutritional therapy can effectively correct clinical hypoproteinemia and reduce the occurrence of adverse clinical outcomes. At present, clinically, hypoproteinemia can be treated by transfusing human albumin. Related studies have shown that intravenous infusion of human albumin can increase the body's protein level, increase blood volume and maintain plasma colloidal osmotic pressure. However, this exogenous supplement of human albumin not only lacks certain essential amino acids for the human body and has a short half-life, but also has a low recycling rate after being decomposed and resynthesized into its own protein after being transfused into the human body. It cannot improve the patient's nutritional status and is not ideal in reducing the incidence of complications and improving clinical prognosis. In addition, high-protein, high-calorie diets such as natural food protein or whole protein (protein powder) are also one of the ways to clinically intervene in hypoproteinemia. However, patients with hypoproteinemia have adverse symptoms such as gastrointestinal mucosal atrophy, decreased gastric acid secretion, decreased digestive enzymes, slow intestinal motility and intestinal wall edema, which cause the patient's tolerance to eating to weaken, leading to protein digestion and absorption disorders. The decomposition, digestion and absorption of dietary protein takes 4-6 hours, and it is difficult for patients with hypoproteinemia to quickly absorb and utilize it. Exploring and developing functional foods that are conducive to rapid absorption and utilization by the body, increase serum protein content, and improve metabolic microcirculation is an important means of clinical nutritional intervention in the future. Summary of the invention

[0004] The purpose of the present application is to provide an albumin peptide composition for improving hypoproteinemia, which can effectively provide high-quality nutrition for the body, is beneficial to postoperative recovery, helps supplement protein for patients with hypoproteinemia, and helps the body's albumin synthesis, as well as a preparation method and application thereof.

[0005] In order to achieve the above application purpose, the technical solution adopted in this application is as follows: In a first aspect of the present application, an albumin peptide composition for improving hypoproteinemia is provided, comprising the following raw materials in parts by weight: 12-20 parts of albumin peptide, 1-3 parts of oligoalbumin peptide concentrate, 4-9 parts of rice protein peptide, 1-4 parts of liver protein hydrolysate, 0.05-0.1 parts of vitamin C, 1-3 parts of xylitol, 1-3 parts of oligofructose, 0.5-2 parts of stachyose, 0.05-0.2 parts of yeast glucan, 0.008-0.04 parts of taurine, 0.0001-0.0002 parts of sucralose, 2-10 parts of apple juice, and 2-10 parts of blueberry juice.

[0006] According to some embodiments of the albumin peptide composition for improving hypoproteinemia described in the present application, the composition includes the following raw materials in parts by weight: 15-18 parts of albumin peptide, 1-2 parts of oligoalbumin peptide concentrate, 5-8 parts of rice protein peptide, 2-3 parts of liver protein hydrolysate, 0.08-0.1 parts of vitamin C, 1.2-2.5 parts of xylitol, 1.2-2.5 parts of oligofructose, 1.2-1.8 parts of stachyose, 0.08-0.12 parts of yeast glucan, 0.01-0.03 parts of taurine, 0.0001-0.0002 parts of sucralose, 5-8 parts of apple juice, and 5-8 parts of blueberry juice.

[0007] According to some embodiments of the albumin peptide composition for improving hypoproteinemia described in the present application, the composition includes the following raw materials in parts by mass: 16 parts of albumin peptide, 2 parts of oligoalbumin peptide concentrate, 6 parts of rice protein peptide, 2 parts of liver protein hydrolysate, 0.08 parts of vitamin C, 2 parts of xylitol, 2 parts of oligofructose, 1.2 parts of stachyose, 0.1 parts of yeast glucan, 0.02 parts of taurine, 0.0001 parts of sucralose, 6 parts of apple juice, and 5 parts of blueberry juice.

[0008] Albumin peptides are extracted from egg whites and converted into small molecule peptides through enzymatic cleavage technology to produce albumin peptides. Albumin peptides contain 20 kinds of amino acids required by the human body, including non-essential amino acids, which can supplement the various amino acids required by the body. At the same time, it has a similar composition ratio to human serum protein and can replace human serum protein to assist the metabolism of various substances in the body.

[0009] Oligoalbumin peptide concentrate is made from chicken egg white, with the addition of auxiliary materials such as protease, with or without food additives, and is obtained through enzymatic hydrolysis, filtration, concentration and ultrafiltration to obtain small molecule peptides with biological activity.

[0010] Rice protein peptide has multiple functions such as promoting bone formation and preventing osteoporosis. It also has the functions of protecting gastric mucosa and resisting ulcers, promoting cell division and repairing damaged skin. Studies have shown that rice protein peptide has the ability to scavenge DPPH free radicals.

[0011] Pork liver protein hydrolysate is a biological product produced using pig liver as raw material using biological extraction technology, which has the functions of improving immunity and repairing liver damage. It is a mixture of biologically active peptides, nucleotides and amino acids separated and purified from pig liver. It has a higher concentration of active substances and a smaller molecular weight, and is easier to be ingested and absorbed by the human body in large quantities.

[0012] Vitamin C is a water-soluble vitamin that participates in the body's complex metabolic processes, can promote growth and enhance resistance to disease, and can be used as a nutritional supplement and antioxidant.

[0013] Xylitol is a sweetener and an intermediate in the normal sugar metabolism of the human body. Xylitol can prevent tooth decay, freshen breath, enhance the body's immunity, replenish energy, and improve sugar metabolism.

[0014] Oligosaccharides are a prebiotic that helps promote the growth and reproduction of beneficial intestinal bacteria, maintain a balanced intestinal flora, and promote digestion and immune system health. Oligosaccharides also help increase calcium absorption, which is important for bone health, especially for people with osteoporosis or bone problems.

[0015] Stachyose has the effects of regulating intestinal flora, moistening the intestines and promoting bowel movements, lowering blood lipids, etc. It can balance the microecology and promote the body's immunity.

[0016] Yeast glucan can enhance the body's immunity by activating immune cells, increasing the number of white blood cells, and resisting the invasion of various pathogens; yeast glucan can also stimulate the immune system and increase the body's own resistance, thus preventing and treating various diseases.

[0017] Taurine can effectively promote the metabolism of nutrients and improve the body's antioxidant capacity; it can effectively enhance the body's immunity, participate in neuroendocrine regulation, and enhance myocardial contractility.

[0018] Sucralose is a high-intensity sweetener with pure sweetness and low calories. Adding it to food can improve the taste of food and increase appetite. Sucralose has the characteristics of low calories, high sweetness, high safety and good flavor.

[0019] Apple juice is a drink that improves health and is a source of soluble and insoluble fiber. Apple juice has the effect of accelerating intestinal peristalsis. Apple juice can absorb bacteria and toxins in the intestines. In addition, the tannic acid and fruit acid in apple juice can reduce the accumulation of cholesterol in the body and help lower blood lipids.

[0020] Blueberry juice is rich in vitamins, carbohydrates, proteins and other nutrients. Drinking it in moderation can provide energy to the body and supplement nutrition. In addition, blueberry juice contains dietary fiber, which can promote intestinal peristalsis, facilitate food digestion and absorption, and thus help promote defecation.

[0021] According to some embodiments of the albumin peptide composition for improving hypoproteinemia described in the present application, the oligoalbumin peptide concentrate is an egg white oligoalbumin peptide concentrate.

[0022] According to some embodiments of the albumin peptide composition for improving hypoproteinemia described in the present application, the liver protein hydrolysate is porcine liver protein hydrolysate.

[0023] The second aspect of the present application provides a method for preparing the albumin peptide composition for improving hypoproteinemia as described in the first aspect of the present application, comprising the following steps: mixing and sterilizing the raw materials to obtain the albumin peptide composition for improving hypoproteinemia.

[0024] According to some embodiments of the preparation method described in the present application, the mixing temperature is 35-50° C., and the mixing time is 10-15 min.

[0025] According to some embodiments of the preparation method described in the present application, the sterilization is UHT sterilization.

[0026] According to some embodiments of the preparation method described in the present application, the temperature of the UHT sterilization is 140-150° C., and the time of the UHT sterilization is 3-6 s.

[0027] The third aspect of the present application provides an application of the albumin peptide composition for improving hypoproteinemia described in the first aspect of the present application or the albumin peptide composition for improving hypoproteinemia obtained by the preparation method described in the second aspect of the present application in the treatment of hypoproteinemia.

[0028] In a fourth aspect of the present application, a drug for treating hypoproteinemia is provided, comprising the albumin peptide composition for improving hypoproteinemia described in the first aspect of the present application or the albumin peptide composition for improving hypoproteinemia obtained by the preparation method described in the second aspect of the present application.

[0029] Compared with the prior art, the beneficial effects of the present application are as follows: the albumin peptide composition for improving hypoproteinemia described in the present application can effectively provide high-quality nutrition for the body, is beneficial to postoperative recovery, helps to supplement protein for patients with hypoproteinemia, and helps the body's albumin synthesis. DETAILED DESCRIPTION

[0030] In order to make the technical problems, technical solutions and beneficial effects to be solved by the present application more clearly understood, the present application is further described in detail below in conjunction with the embodiments. It should be understood that the specific embodiments described herein are only used to explain the present application and are not used to limit the present application.

[0031] In this application, the term "and / or" describes the association relationship of associated objects, indicating that there may be three relationships. For example, A and / or B can mean: A exists alone, A and B exist at the same time, and B exists alone. A and B can be singular or plural. The character " / " generally indicates that the associated objects are in an "or" relationship.

[0032] In this application, "at least one" means one or more, and "plurality" means two or more. "At least one of the following" or similar expressions refers to any combination of these items, including any combination of single items or plural items. For example, "at least one of a, b, or c", or "at least one of a, b, and c" can all mean: a, b, c, ab (i.e., a and b), ac, bc, or abc, where a, b, and c can be single or multiple.

[0033] It should be understood that in the various embodiments of the present application, the size of the serial numbers of the above-mentioned processes does not mean the order of execution, some or all of the steps can be executed in parallel or sequentially, and the execution order of each process should be determined by its function and internal logic, and should not constitute any limitation on the implementation process of the embodiments of the present application.

[0034] The terms used in the embodiments of the present application are only for the purpose of describing specific embodiments, and are not intended to limit the present application. The singular forms "a", "said" and "the" used in the embodiments of the present application and the appended claims are also intended to include plural forms, unless the context clearly indicates other meanings.

[0035] The weight of the relevant components mentioned in the embodiment description of the present application can not only refer to the specific content of each component, but also indicate the proportional relationship between the weights of the components. Therefore, as long as the content of the relevant components is proportionally enlarged or reduced according to the embodiment description of the present application, it is within the scope disclosed in the embodiment description of the present application. Specifically, the mass described in the embodiment description of the present application can be a mass unit known in the chemical industry such as µg, mg, g, kg, etc.

[0036] Example 1 An albumin peptide composition for improving hypoproteinemia comprises the following raw materials in parts by weight: 12 g of albumin peptide, 1 g of oligoalbumin peptide concentrate, 4 g of rice protein peptide, 2 g of liver protein hydrolysate, 0.1 g of vitamin C, 1 g of xylitol, 2 g of oligofructose, 1 g of stachyose, 0.2 g of yeast glucan, 0.02 g of taurine, 0.0001 g of sucralose, 3 g of apple juice and 5 g of blueberry juice.

[0037] The method for preparing the albumin peptide composition for improving hypoproteinemia described in Example 1 comprises the following steps: mixing the raw materials at a temperature of 35°C for 15 minutes, and UHT sterilizing the mixture at a sterilization temperature of 145°C for 6 seconds to obtain the albumin peptide composition for improving hypoproteinemia.

[0038] Example 2 An albumin peptide composition for improving hypoproteinemia comprises the following raw materials in parts by weight: 15 g of albumin peptide, 2 g of oligoalbumin peptide concentrate, 6 g of rice protein peptide, 2 g of liver protein hydrolysate, 0.05 g of vitamin C, 2 g of xylitol, 2 g of oligofructose, 1 g of stachyose, 0.15 g of yeast glucan, 0.02 g of taurine, 0.0001 g of sucralose, 5 g of apple juice and 3 g of blueberry juice.

[0039] The method for preparing the albumin peptide composition for improving hypoproteinemia described in Example 2 comprises the following steps: mixing the raw materials at a temperature of 35°C for 15 minutes, and UHT sterilizing the mixture at a sterilization temperature of 145°C for 6 seconds to obtain the albumin peptide composition for improving hypoproteinemia.

[0040] Example 3 An albumin peptide composition for improving hypoproteinemia comprises the following raw materials in parts by weight: 20 g of albumin peptide, 3 g of oligoalbumin peptide concentrate, 9 g of rice protein peptide, 4 g of liver protein hydrolysate, 0.1 g of vitamin C, 3 g of xylitol, 3 g of oligofructose, 2 g of stachyose, 0.2 g of yeast glucan, 0.02 g of taurine, 0.0001 g of sucralose, 10 g of apple juice and 10 g of blueberry juice.

[0041] The method for preparing the albumin peptide composition for improving hypoproteinemia described in Example 3 comprises the following steps: mixing the raw materials at a temperature of 50°C for 15 minutes, and UHT sterilizing the mixture at a sterilization temperature of 150°C for 6 seconds to obtain the albumin peptide composition for improving hypoproteinemia.

[0042] Comparative Example 1 The difference between Comparative Example 1 and Example 1 is that the albumin peptide composition for improving hypoproteinemia described in Comparative Example 1 does not contain raw liver protein hydrolysate.

[0043] Comparative Example 2 The only difference between Comparative Example 2 and Example 1 is that the albumin peptide composition for improving hypoproteinemia described in Comparative Example 2 does not contain raw material albumin peptide.

[0044] Comparative Example 3 The only difference between Comparative Example 3 and Example 1 is that the albumin peptide composition for improving hypoproteinemia described in Comparative Example 3 does not contain raw rice protein peptides and oligoalbumin peptide concentrate.

[0045] Study on the efficacy of the albumin peptide composition for improving hypoproteinemia described in Example 1 of the present application and the albumin peptide composition for improving hypoproteinemia described in Comparative Examples 1-3: Research Methodology: Dosage: The subject orally takes the albumin peptide composition for improving hypoproteinemia described in Example 1 of the present application or the albumin peptide composition for improving hypoproteinemia described in Comparative Examples 1-3, 1 g at a time, once a day.

[0046] Trial grouping: Without changing the basic treatment method, comparative examples 1-3 are used as the control group, and Example 1 is used as the experimental group. It is planned to include 40 subjects (the dropout rate is calculated as 20%). The subjects are randomly assigned to the control group and the experimental group in a 1:1 ratio. The trial period is 30 days, 0-21 days are the product intervention period, and 22-30 days are the product follow-up period.

[0047] Sample collection: Blood samples were collected on days 0, 21±2 days, and 30±2 days.

[0048] The effects of the albumin peptide composition for improving hypoproteinemia described in Example 1 of the present application and the albumin peptide composition for improving hypoproteinemia described in Comparative Examples 1-3 on the total plasma protein of the body are shown in Table 1: Table 1

[0049] Note: Before taking is the total protein content in the subject's plasma before taking the drug; After taking is the total protein content in the subject's plasma after taking the drug.

[0050] It can be seen from Table 1 that the albumin peptide composition for improving hypoproteinemia described in the present application is more conducive to the synthesis of total protein in the body than the comparative example. The albumin peptide composition for improving hypoproteinemia described in the comparative example can significantly reduce the synthesis of total plasma protein due to the lack of liver protein hydrolysate, albumin peptide, rice protein peptide and albumin oligopeptide concentrate. Among them, the lack of albumin peptide component has the greatest impact on total plasma protein.

[0051] The effects of the albumin peptide composition for improving hypoproteinemia described in Example 1 of the present application and the albumin peptide composition for improving hypoproteinemia described in Comparative Examples 1-3 on body albumin, the test results are shown in Table 2: Table 2

[0052] Note: Before taking is the albumin content in the subject's plasma before taking the drug; After taking is the albumin content in the subject's plasma after taking the drug.

[0053] It can be seen from Table 2 that the albumin composition described in the present application is more conducive to the synthesis of albumin in the body than the comparative example. The comparative example will significantly reduce the synthesis of albumin due to the lack of liver protein hydrolysate, albumin peptide, rice protein peptide and albumin oligopeptide concentrate, among which the lack of albumin peptide component has the greatest impact on albumin.

[0054] The effects of the albumin peptide composition for improving hypoproteinemia described in Example 1 of the present application and the albumin peptide composition for improving hypoproteinemia described in Comparative Examples 1-3 on transferrin in the body are shown in Table 3: Table 3

[0055] Note: Before taking is the transferrin content in the subject's plasma before taking the drug; After taking is the content of transferrin in the subject's plasma after taking the drug.

[0056] It can be seen from Table 3 that the albumin composition described in the present application is more conducive to the synthesis of transferrin in the body than the comparative example. The albumin composition described in the comparative example can significantly reduce the synthesis of transferrin due to the lack of liver protein hydrolysate, albumin peptide, rice protein peptide and albumin oligopeptide concentrate.

[0057] The effects of the albumin peptide composition for improving hypoproteinemia described in Example 1 of the present application and the albumin peptide composition for improving hypoproteinemia described in Comparative Examples 1-3 on inflammation in the body are tested as shown in Table 4: Table 4

[0058] Note: Before taking is the inflammatory condition of the subject before taking the drug; After taking is the inflammation condition of the subject after taking the drug.

[0059] It can be seen from Table 4 that the albumin peptide composition for improving hypoproteinemia described in the present application is more helpful in eliminating inflammation than the comparative example, while the albumin peptide composition for improving hypoproteinemia described in the comparative example has poor inflammation reducing effect due to the lack of liver protein hydrolysate, albumin peptide, rice protein peptide and albumin oligopeptide concentrate, among which the inflammation reducing effect is the worst due to the lack of rice protein peptide and albumin oligopeptide.

[0060] The above description is only a preferred embodiment of the present application and is not intended to limit the present application. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present application should be included in the protection scope of the present application.

Claims

1. An albumin peptide composition for improving hypoproteinemia, characterized in that: The invention comprises the following raw materials in parts by weight: 12-20 parts of albumin peptide, 1-3 parts of oligoalbumin peptide concentrate, 4-9 parts of rice protein peptide, 1-4 parts of liver protein hydrolysate, 0.05-0.1 parts of vitamin C, 1-3 parts of xylitol, 1-3 parts of oligofructose, 0.5-2 parts of stachyose, 0.05-0.2 parts of yeast glucan, 0.008-0.04 parts of taurine, 0.0001-0.0002 parts of sucralose, 2-10 parts of apple juice and 2-10 parts of blueberry juice.

2. The albumin peptide composition for improving hypoproteinemia according to claim 1, characterized in that: The invention comprises the following raw materials in parts by weight: 15-18 parts of albumin peptide, 1-2 parts of oligoalbumin peptide concentrate, 5-8 parts of rice protein peptide, 2-3 parts of liver protein hydrolysate, 0.08-0.1 parts of vitamin C, 1.2-2.5 parts of xylitol, 1.2-2.5 parts of oligofructose, 1.2-1.8 parts of stachyose, 0.08-0.12 parts of yeast glucan, 0.01-0.03 parts of taurine, 0.0001-0.0002 parts of sucralose, 5-8 parts of apple juice and 5-8 parts of blueberry juice.

3. The albumin peptide composition for improving hypoproteinemia according to claim 1, characterized in that: The invention comprises the following raw materials in parts by weight: 16 parts of albumin peptide, 2 parts of oligoalbumin peptide concentrate, 6 parts of rice protein peptide, 2 parts of liver protein hydrolysate, 0.08 parts of vitamin C, 2 parts of xylitol, 2 parts of oligofructose, 1.2 parts of stachyose, 0.1 parts of yeast glucan, 0.02 parts of taurine, 0.0001 parts of sucralose, 6 parts of apple juice and 5 parts of blueberry juice.

4. The albumin peptide composition for improving hypoproteinemia according to claim 1, characterized in that: The oligoalbumin peptide concentrate is an hen egg white oligoalbumin peptide concentrate.

5. The albumin peptide composition for improving hypoproteinemia according to claim 1, characterized in that: The liver protein hydrolysate is pig liver protein hydrolysate.

6. The method for preparing the albumin peptide composition for improving hypoproteinemia according to claim 1 or 2, characterized in that: The following steps are involved: The raw materials are mixed and sterilized to obtain the albumin peptide composition for improving hypoproteinemia.

7. The preparation method according to claim 6, characterized in that: The mixing temperature is 35-50° C., and the mixing time is 10-15 min.

8. The preparation method according to claim 6, characterized in that: The sterilization is UHT sterilization; preferably, the temperature of the UHT sterilization is 140-150° C., and the time of the UHT sterilization is 3-6 seconds.

9. Use of the albumin peptide composition for improving hypoproteinemia according to any one of claims 1 to 2 or the albumin peptide composition for improving hypoproteinemia obtained by the preparation method according to any one of claims 6 to 8 in the preparation of a drug for treating hypoproteinemia.

10. A drug for treating hypoproteinemia, characterized in that: The invention comprises the albumin peptide composition for improving hypoproteinemia as described in any one of claims 1 to 2 or the albumin peptide composition for improving hypoproteinemia obtained by the preparation method as described in any one of claims 6 to 8.

Images